GSK - GSK Q1 sales soar on Shingrix vaccine COVID therapy Xevudy; confirms outlook impact on Xevudy margins in FY22

GlaxoSmithKline's (NYSE:GSK) Q1 revenue rose on the back of strong performance from Specialty Medicines segment, while the company reconfirmed its guidance and said that the spin-off of consumer unit Haleon was on track for July. Q1 sales rose +32% Y/Y (at AER) Y/Y £9.78B. The company said the rise Group turnover reflected a strong performance in Commercial Operations in the three product groups and Consumer Healthcare. Sales of COVID-19 therapy Xevudy were ~£1.31B and contributed 25 percentage points of growth in Q1 to Commercial Operations. "Our results reflect further good momentum across specialty medicines and vaccines, including the return to strong sales growth for Shingrix and continuing pipeline progress," said GSK CEO Emma Walmsley. The British drugmaker added that Specialty Medicines included the positive impact of international tender phasing, Vaccines benefited from Shingrix post-pandemic recovery and retail buy-in in the U.S. and General Medicines reflected growth from lung disease therapy Trelegy and recovery of

For further details see:

GSK Q1 sales soar on Shingrix vaccine, COVID therapy Xevudy; confirms outlook, impact on Xevudy margins in FY22